http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 01 Jul 2026 16:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++OPKO+HEALTH%2C+INC.++++++++++++++++++++++Filed+by%3A+FROST+PHILLIP+MD+ET+AL/26720567.html si-local-file:///var/storage/secattach/20260701/26720567.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++OPKO+HEALTH%2C+INC.++++++++++++++++++++++Filed+by%3A+FROST+PHILLIP+MD+ET+AL/26720567.html Wed, 01 Jul 2026 16:05:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++OPKO+HEALTH%2C+INC.++++++++++++++++++++++Filed+by%3A+FROST+PHILLIP+MD+ET+AL/26720567.html si-local-file:///var/storage/secattach/20260701/26720567.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++OPKO+HEALTH%2C+INC.++++++++++++++++++++++Filed+by%3A+FROST+PHILLIP+MD+ET+AL/26720567.html Wed, 01 Jul 2026 16:05:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+Lachman+Prem+A/26674260.html si-local-file:///var/storage/secattach/20260622/26674260.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+Lachman+Prem+A/26674260.html Mon, 22 Jun 2026 17:38:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+Lachman+Prem+A/26674260.html si-local-file:///var/storage/secattach/20260622/26674260.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+Lachman+Prem+A/26674260.html Mon, 22 Jun 2026 17:38:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+MEDEL+ROGER+MD/26674256.html si-local-file:///var/storage/secattach/20260622/26674256.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+MEDEL+ROGER+MD/26674256.html Mon, 22 Jun 2026 17:37:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+MEDEL+ROGER+MD/26674256.html si-local-file:///var/storage/secattach/20260622/26674256.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+MEDEL+ROGER+MD/26674256.html Mon, 22 Jun 2026 17:37:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+PAGANELLI+JOHN+A/26674254.html si-local-file:///var/storage/secattach/20260622/26674254.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+PAGANELLI+JOHN+A/26674254.html Mon, 22 Jun 2026 17:36:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+PAGANELLI+JOHN+A/26674254.html si-local-file:///var/storage/secattach/20260622/26674254.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+PAGANELLI+JOHN+A/26674254.html Mon, 22 Jun 2026 17:36:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+PFENNIGER+RICHARD+C+JR/26674248.html si-local-file:///var/storage/secattach/20260622/26674248.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+PFENNIGER+RICHARD+C+JR/26674248.html Mon, 22 Jun 2026 17:35:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+PFENNIGER+RICHARD+C+JR/26674248.html si-local-file:///var/storage/secattach/20260622/26674248.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+PFENNIGER+RICHARD+C+JR/26674248.html Mon, 22 Jun 2026 17:35:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+UPPALURI+SUBBARAO+V/26674241.html si-local-file:///var/storage/secattach/20260622/26674241.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+UPPALURI+SUBBARAO+V/26674241.html Mon, 22 Jun 2026 17:33:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+UPPALURI+SUBBARAO+V/26674241.html si-local-file:///var/storage/secattach/20260622/26674241.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+UPPALURI+SUBBARAO+V/26674241.html Mon, 22 Jun 2026 17:33:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+Yu+Alice+Lin-Tsing/26674234.html si-local-file:///var/storage/secattach/20260622/26674234.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+Yu+Alice+Lin-Tsing/26674234.html Mon, 22 Jun 2026 17:32:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+Yu+Alice+Lin-Tsing/26674234.html si-local-file:///var/storage/secattach/20260622/26674234.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18++Filed+by%3A+Yu+Alice+Lin-Tsing/26674234.html Mon, 22 Jun 2026 17:32:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18/26665981.html si-local-file:///var/storage/secattach/20260618/26665981.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18/26665981.html Thu, 18 Jun 2026 16:06:00 -0400 O.02783319 OPK http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18/26665981.html si-local-file:///var/storage/secattach/20260618/26665981.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++OPKO+HEALTH%2C+INC.+++++++++For%3A+Jun+18/26665981.html Thu, 18 Jun 2026 16:06:00 -0400 O.02783319 OPK http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html <p>Entera Bio Ltd. (NASDAQ: ENTX) presented preclinical data for two pipeline candidates, EB612 and EB618, at ENDO 2026, the annual meeting of the Endocrine Society, on June 16, 2026. Both programs are being co-developed with OPKO Health Inc. (NASDAQ: OPK) on a 50/50 basis.</p> <p>EB612 is a long-acting PTH(1-34) analog formulated as an oral tablet for hypoparathyroidism. In a thyroparathyroidectomized rat model, daily dosing for seven days restored serum calcium and reduced phosphate to levels comparable to sham control animals. In a minipig model, a single oral dose reached peak plasma levels two to three hours post-dose, with drug detectable in http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html Tue, 16 Jun 2026 08:33:28 -0400 A.50203974 ENTX O.00028300 O.38505617 OPK http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html <p>Entera Bio Ltd. (NASDAQ: ENTX) presented preclinical data for two pipeline candidates, EB612 and EB618, at ENDO 2026, the annual meeting of the Endocrine Society, on June 16, 2026. Both programs are being co-developed with OPKO Health Inc. (NASDAQ: OPK) on a 50/50 basis.</p> <p>EB612 is a long-acting PTH(1-34) analog formulated as an oral tablet for hypoparathyroidism. In a thyroparathyroidectomized rat model, daily dosing for seven days restored serum calcium and reduced phosphate to levels comparable to sham control animals. In a minipig model, a single oral dose reached peak plasma levels two to three hours post-dose, with drug detectable in http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html Tue, 16 Jun 2026 08:33:28 -0400 A.50203974 ENTX O.00028300 O.38505617 OPK http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html <p>Entera Bio Ltd. (NASDAQ: ENTX) presented preclinical data for two pipeline candidates, EB612 and EB618, at ENDO 2026, the annual meeting of the Endocrine Society, on June 16, 2026. Both programs are being co-developed with OPKO Health Inc. (NASDAQ: OPK) on a 50/50 basis.</p> <p>EB612 is a long-acting PTH(1-34) analog formulated as an oral tablet for hypoparathyroidism. In a thyroparathyroidectomized rat model, daily dosing for seven days restored serum calcium and reduced phosphate to levels comparable to sham control animals. In a minipig model, a single oral dose reached peak plasma levels two to three hours post-dose, with drug detectable in http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html Tue, 16 Jun 2026 08:33:28 -0400 A.50203974 ENTX O.00028300 O.38505617 OPK http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html <p>Entera Bio Ltd. (NASDAQ: ENTX) presented preclinical data for two pipeline candidates, EB612 and EB618, at ENDO 2026, the annual meeting of the Endocrine Society, on June 16, 2026. Both programs are being co-developed with OPKO Health Inc. (NASDAQ: OPK) on a 50/50 basis.</p> <p>EB612 is a long-acting PTH(1-34) analog formulated as an oral tablet for hypoparathyroidism. In a thyroparathyroidectomized rat model, daily dosing for seven days restored serum calcium and reduced phosphate to levels comparable to sham control animals. In a minipig model, a single oral dose reached peak plasma levels two to three hours post-dose, with drug detectable in http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html Tue, 16 Jun 2026 08:33:28 -0400 A.50203974 ENTX O.00028300 O.38505617 OPK http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html <p>Entera Bio Ltd. (NASDAQ: ENTX) presented preclinical data for two pipeline candidates, EB612 and EB618, at ENDO 2026, the annual meeting of the Endocrine Society, on June 16, 2026. Both programs are being co-developed with OPKO Health Inc. (NASDAQ: OPK) on a 50/50 basis.</p> <p>EB612 is a long-acting PTH(1-34) analog formulated as an oral tablet for hypoparathyroidism. In a thyroparathyroidectomized rat model, daily dosing for seven days restored serum calcium and reduced phosphate to levels comparable to sham control animals. In a minipig model, a single oral dose reached peak plasma levels two to three hours post-dose, with drug detectable in http://www.streetinsider.com/FDA/ENTERA+BIO+shares+preclinical+data+for+two+pipeline+drugs+at+ENDO+2026/26651078.html Tue, 16 Jun 2026 08:33:28 -0400 A.50203974 ENTX O.00028300 O.38505617 OPK http://www.streetinsider.com/FDA/OPKO+Biologics+presents+preclinical+data+for+acromegaly+drug+candidate/26644405.html <p>OPKO Health Inc. (NASDAQ: OPK) subsidiary OPKO Biologics presented preclinical data for its drug candidate OPK8801001 at ENDO 2026, the Endocrine Society's annual meeting on June 15.</p> <p>The preclinical study data showed that OPK8801001 produced dose-dependent suppression of insulin-like growth factor-1 (IGF-1), which serves as a marker for disease activity in acromegaly. The company reported that in vitro data demonstrated the drug candidate's growth hormone receptor antagonism was approximately 20-fold greater than Pegvisomant, an existing acromegaly therapy.</p> <p>The findings suggest potential for weekly dosing compared to currently available daily treatments for the condition. Moran Golan, Director of Preclinical & Clinical Pharmacology at http://www.streetinsider.com/FDA/OPKO+Biologics+presents+preclinical+data+for+acromegaly+drug+candidate/26644405.html Mon, 15 Jun 2026 08:00:22 -0400 O.02783319 OPK http://www.streetinsider.com/FDA/OPKO+Biologics+presents+preclinical+data+for+acromegaly+drug+candidate/26644405.html <p>OPKO Health Inc. (NASDAQ: OPK) subsidiary OPKO Biologics presented preclinical data for its drug candidate OPK8801001 at ENDO 2026, the Endocrine Society's annual meeting on June 15.</p> <p>The preclinical study data showed that OPK8801001 produced dose-dependent suppression of insulin-like growth factor-1 (IGF-1), which serves as a marker for disease activity in acromegaly. The company reported that in vitro data demonstrated the drug candidate's growth hormone receptor antagonism was approximately 20-fold greater than Pegvisomant, an existing acromegaly therapy.</p> <p>The findings suggest potential for weekly dosing compared to currently available daily treatments for the condition. Moran Golan, Director of Preclinical & Clinical Pharmacology at http://www.streetinsider.com/FDA/OPKO+Biologics+presents+preclinical+data+for+acromegaly+drug+candidate/26644405.html Mon, 15 Jun 2026 08:00:22 -0400 O.02783319 OPK http://www.streetinsider.com/Press+Releases/Preclinical+Data+for+OPKO+Biologics%26apos%3B+OPK8801001+in+Acromegaly+Presented+at+ENDO+2026/26644383.html <p align="justify">MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- <strong>OPKO Health, Inc. (NASDAQ: OPK)</strong> OPKO Biologics, an OPKO Health company, presented preclinical data for OPK8801001 at ENDO 2026, the Endocrine Society’s annual meeting. The poster, “Production and Characterization of OPK8801001, a Novel Long-Acting hGH Receptor Antagonist for the Treatment of Acromegaly,” available <a target="_blank" href="https://www.globenewswire.com/Tracker?data=nAzvr3ADGFxB2sqyTHnBzSefzF3234HIXZNTYg_W1-4BDf4JBFdDlNzMvLi_4-yTKM69Tpxzd6O69yd4-GuSjMG8UzeUR5zUArfOI0LRJLA=" rel="nofollow" target="_blank">here</a>, was presented by Moran Golan, Ph.D., Director of Preclinical &amp; Clinical Pharmacology at OPKO Biologics.</p> <p align="justify"><em>In vivo</em> data showed that OPK8801001 produced robust, dose-dependent, sustained suppression of insulin-like growth factor-1 (IGF-1), a marker of disease activity in acromegaly. The findings http://www.streetinsider.com/Press+Releases/Preclinical+Data+for+OPKO+Biologics%26apos%3B+OPK8801001+in+Acromegaly+Presented+at+ENDO+2026/26644383.html Mon, 15 Jun 2026 08:00:00 -0400 O.02783319 OPK http://www.streetinsider.com/Press+Releases/Preclinical+Data+for+OPKO+Biologics%26apos%3B+OPK8801001+in+Acromegaly+Presented+at+ENDO+2026/26644383.html <p align="justify">MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- <strong>OPKO Health, Inc. (NASDAQ: OPK)</strong> OPKO Biologics, an OPKO Health company, presented preclinical data for OPK8801001 at ENDO 2026, the Endocrine Society’s annual meeting. The poster, “Production and Characterization of OPK8801001, a Novel Long-Acting hGH Receptor Antagonist for the Treatment of Acromegaly,” available <a target="_blank" href="https://www.globenewswire.com/Tracker?data=nAzvr3ADGFxB2sqyTHnBzSefzF3234HIXZNTYg_W1-4BDf4JBFdDlNzMvLi_4-yTKM69Tpxzd6O69yd4-GuSjMG8UzeUR5zUArfOI0LRJLA=" rel="nofollow" target="_blank">here</a>, was presented by Moran Golan, Ph.D., Director of Preclinical &amp; Clinical Pharmacology at OPKO Biologics.</p> <p align="justify"><em>In vivo</em> data showed that OPK8801001 produced robust, dose-dependent, sustained suppression of insulin-like growth factor-1 (IGF-1), a marker of disease activity in acromegaly. The findings http://www.streetinsider.com/Press+Releases/Preclinical+Data+for+OPKO+Biologics%26apos%3B+OPK8801001+in+Acromegaly+Presented+at+ENDO+2026/26644383.html Mon, 15 Jun 2026 08:00:00 -0400 O.02783319 OPK